Establishment and characterization of a new mantle cell lymphoma cell line M-1.
A new mantle cell lymphoma cell line, M-1, was established from peripheral blood mononuclear cells of a patient with a diagnosis of blastoid variant of mantle cell lymphoma in leukemic phase. This cell line showed cell surface antigens identical to the original tumor and demonstrated the profile of a mature B-cell phenotype typical of mantle cell lymphoma: positive for CD5, CD19, CD20, sIgM and FMC7, and negative for CD3, CD10 and CD23. Cytogenetically, the M-1 cell line showed chromosomal alterations similar to the initial clinical specimen, among which a translocation t(11;14) (q13;q32) resulting in the overexpression of cyclin D1 as well as additional abnormalities involving chromosomes 3, 9 and 10. This cell line was used as a model to investigate the activity of the three drugs doxorubicin, cyclophosphamide and vincristine, commonly used in the treatment of mantle cell lymphoma patients. The effect of the drugs was evaluated by a 24 h cytotoxicity test and a 7-days anti-proliferation test using a microculture tetrazolium-based assay (MTT). Both assays indicated a higher sensitivity of the cell line to vincristine when compared to doxorubicin and cyclophosphamide. The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established.
Goy
Andre
A
Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas 77030, USA. ahgoy@mail.mdanderson.org
Remache
Yvonne K
YK
Gu
Jun
J
Stewart
John
J
Hayes
Kimberly J
KJ
Gold
David
D
Jiang
Yunfang
Y
Barkoh
Bedia A
BA
Katz
Ruth
R
Cabanillas
Fernando
F
Gilles
Frederic
F
D000954:Antigens, Surface / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics; D019938:Cyclin D1 / Q000378:metabolism; D003520:Cyclophosphamide / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D006801:Humans; D016130:Immunophenotyping; D020522:Lymphoma, Mantle-Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014750:Vincristine / Q000494:pharmacology
D000954:Antigens, Surface; D000970:Antineoplastic Agents; D019938:Cyclin D1; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide